Balancing Speed, Quality & Digital Transformations
On-demand webinar
Fill out the form below to access the full webinar
Take a sneak peak
Not sure if this webinar is for you? Here's a short snippet to get a feel for what this webinar will go over.
Webinar Abstract:
The pharmaceutical development and technology transfer landscape is undergoing rapid evolution, making strategic agility a critical factor for success. This presentation examines the key challenges and opportunities faced by Contract Development and Manufacturing Organizations (CDMOs) in this dynamic environment.
A central focus is on the global strategy of CDMOs, particularly the need for scale flexibility to meet the growing and diverse demands of clients. Strategies for adapting operations while maintaining efficiency and client satisfaction are explored, alongside the delicate balance between speed and quality in an industry where time-to-market is vital.
Additionally, the transformative role of digitalization in technology transfer is highlighted, with a focus on the implementation of electronic Batch Records (eBR) and other digital solutions. These innovations promise to streamline operations, enhance efficiency, and redefine the future of process development.
This presentation provides a comprehensive overview of the evolving landscape, offering insights into how CDMOs can leverage technology and strategic agility to thrive in a competitive and fast-paced industry.
Learn from the expert

Watson Neto
Director, Process Transfer & Validation
Watson Neto
Director, Process Transfer & Validation
AGC Biologics
Watson Neto is the Director of the Process Transfer & Validation team at AGC Biologics in Copenhagen, where he leads a team of 40 talented scientists and engineers. His team is dedicated to ensuring seamless technology transfer and validation activities, enabling the transition of processes from development to large-scale manufacturing within AGC Biologics and across its global network. They also facilitate the transfer of client processes into large-scale manufacturing operations, delivering a streamlined and efficient experience for customers.
Watson holds a degree in Biological Engineering from the University of Algarve in Portugal and a Ph.D. in Bioprocessing Technology from the Technical University of Denmark. His expertise lies in downstream processing, a field in which he has built a distinguished career in the biotechnology and pharmaceutical sectors.
Watson’s professional journey began with groundbreaking research on enzyme immobilization for large-scale industrial applications in biocatalysis at Purolite in the United Kingdom. He then transitioned to Novo Nordisk A/S in Denmark, where he contributed to the global manufacturing of insulin as a production scientist.
In 2019, Watson joined AGC Biologics in Copenhagen as a Downstream Scientist in the Process Transfer group. His leadership skills and technical expertise quickly earned him promotions—first to Team Leader for the Downstream team in 2020, and then to Director in 2022. As part of a recent reorganization within the PD-MSAT (Process Development and Manufacturing Science and Technology) division, Watson’s team expanded significantly with the merging of the Process Transfer and Process Validation teams. This strategic move aims to enhance transfer and validation workflows, ensuring a more seamless experience for AGC Biologics’ customers.
With a strong foundation in science, leadership, and innovation, Watson continues to drive excellence in process transfer and validation, contributing to AGC Biologics’ mission of delivering high-quality biopharmaceutical solutions to clients worldwide